Literature DB >> 1540400

HIV-1 replication and potential targets for intervention.

M Stevenson1, M Bukrinsky, S Haggerty.   

Abstract

Intense research into fundamental processes of human immunodeficiency syndrome type 1 (HIV-1) replication has yielded knowledge that in many aspects equals or exceeds that of the oncogenic retroviruses. The availability of sensitive virus detection methods has allowed a more thorough characterization of the biology of virus persistence and latency in vivo and removed the dependence on in vitro models. As a clearer picture of the pattern of HIV-1 replication in vivo evolves, it becomes apparent that HIV-1 biology is distinct from that of the prototypic oncogenic retroviruses in several key aspects, particularly with regard to host cell range and determinants of viral permissiveness. In this respect it may be appropriate to examine the lentivirus, rather than the oncovirus model system to better understand the biology and pathogenesis of HIV-1 infection. This synopsis of recent and ongoing research developments in HIV-1 replication and pathogenesis emphasizes the determinants of host cell permissiveness, early events in virus replication, and underlying features in HIV-1 cytopathogenesis. In addition, basic viral replication processes which can be exploited for therapeutic intervention are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540400     DOI: 10.1089/aid.1992.8.107

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Nucleotide composition as a driving force in the evolution of retroviruses.

Authors:  E C Bronson; J N Anderson
Journal:  J Mol Evol       Date:  1994-05       Impact factor: 2.395

2.  Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.

Authors:  M I Bukrinsky; N Sharova; M P Dempsey; T L Stanwick; A G Bukrinskaya; S Haggerty; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

3.  Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.

Authors:  J A Turpin; R W Buckheit; D Derse; M Hollingshead; K Williamson; C Palamone; M C Osterling; S A Hill; L Graham; C A Schaeffer; M Bu; M Huang; W M Cholody; C J Michejda; W G Rice
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 4.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.

Authors:  C A Spina; J C Guatelli; D D Richman
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in Vpu-induced degradation in the endoplasmic reticulum.

Authors:  M J Vincent; N U Raja; M A Jabbar
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention.

Authors:  L Dubrovsky; P Ulrich; G J Nuovo; K R Manogue; A Cerami; M Bukrinsky
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

8.  Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.

Authors:  M I Anazodo; M A Wainberg; A D Friesen; J A Wright
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  HIV-particles in spermatozoa of patients with AIDS and their transfer into the oocyte.

Authors:  B Baccetti; A Benedetto; A G Burrini; G Collodel; E C Ceccarini; N Crisà; A Di Caro; M Estenoz; A R Garbuglia; A Massacesi
Journal:  J Cell Biol       Date:  1994-11       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.